These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Influence of calcium antagonists on thrombin-induced calcium mobilization and platelet-vessel wall interactions. Rao GH; Smith CM; White JG Biochem Med Metab Biol; 1992 Jun; 47(3):226-31. PubMed ID: 1627353 [TBL] [Abstract][Full Text] [Related]
45. Drug effects on platelet adherence to collagen and damaged vessel walls. Packham MA; Cazenave JP; Kinlough-Rathbone RL; Mustard JF Adv Exp Med Biol; 1978; 109():253-76. PubMed ID: 364949 [TBL] [Abstract][Full Text] [Related]
46. Expression of the platelet procoagulant activity in vivo in thrombus formation in an extracorporeal shunt in the rat. Shand RA; Smith JR; Wallis RB Thromb Res; 1984 Nov; 36(3):223-32. PubMed ID: 6096983 [TBL] [Abstract][Full Text] [Related]
47. Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol. Deible CR; Petrosko P; Johnson PC; Beckman EJ; Russell AJ; Wagner WR Biomaterials; 1999 Jan; 20(2):101-9. PubMed ID: 10022779 [TBL] [Abstract][Full Text] [Related]
48. Kinetics of fibrinogen and platelet adherence to biomaterials. Roohk HV; Pick J; Hill R; Hung E; Bartlett RH Trans Am Soc Artif Intern Organs; 1976; 22():1-8. PubMed ID: 951830 [TBL] [Abstract][Full Text] [Related]
49. Effects of nitric oxide (NO) and soluble nucleoside triphosphate diphosphohydrolase (NTPDase) on inhibition of platelet deposition in vitro. Ramamurthi A; Robson SC; Lewis RS Thromb Res; 2001 May; 102(4):331-41. PubMed ID: 11369426 [TBL] [Abstract][Full Text] [Related]
51. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo. Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956 [TBL] [Abstract][Full Text] [Related]
52. Evidence for a role in thrombus stabilization for thromboxane A2 in human platelet deposition on collagen. Wagner WR; Hubbell JA J Lab Clin Med; 1992 Jun; 119(6):690-7. PubMed ID: 1534345 [TBL] [Abstract][Full Text] [Related]
53. Inhibition of platelet recruitment to arterial lesions by predeposition of platelets containing encapsulated iloprost. Pfliegler G; el-Gamal B; Badimon JJ; Badimon L; Crawford N Thromb Haemost; 1994 Oct; 72(4):604-10. PubMed ID: 7533337 [TBL] [Abstract][Full Text] [Related]
54. Development and evaluation of a new polymeric material for small caliber vascular prostheses. Chaikof EL; Coleman JE; Ramberg K; Connolly RJ; Merrill EW; Callow AD J Surg Res; 1989 Sep; 47(3):193-9. PubMed ID: 2770275 [TBL] [Abstract][Full Text] [Related]
55. Deposition of fibrinogen on the surface of in vitro thrombi prevents platelet adhesion. Owaynat H; Yermolenko IS; Turaga R; Lishko VK; Sheller MR; Ugarova TP Thromb Res; 2015 Dec; 136(6):1231-9. PubMed ID: 26482763 [TBL] [Abstract][Full Text] [Related]
56. Gel-filtered human platelets. Ultrastructure, function, and role of proteins in inhibition of aggregation by aspirin. Fine KM; Ashbrook PC; Brigden LP; Maldonado JE; Didishelm P Am J Pathol; 1976 Jul; 84(1):11-24. PubMed ID: 59550 [TBL] [Abstract][Full Text] [Related]
57. Fluorescence labeling to study platelet and leucocyte deposition onto vascular grafts in vitro. Toes GJ; van den Dungen JJ; Haan J; Hermens RA; van Oeveren W Biomaterials; 1999 Oct; 20(20):1951-8. PubMed ID: 10514073 [TBL] [Abstract][Full Text] [Related]
58. Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol. Deible CR; Petrosko P; Johnson PC; Beckman EJ; Russell AJ; Wagner WR Biomaterials; 1998 Oct; 19(20):1885-93. PubMed ID: 9855190 [TBL] [Abstract][Full Text] [Related]
59. PGE1-induced arterial thromboresistance is a vascular property as identified by cross-perfusion technique. Sinzinger H; Neumann I; O'Grady J; Rogatti W; Peskar BA Prostaglandins Leukot Essent Fatty Acids; 1997 Apr; 56(4):325-30. PubMed ID: 9150379 [TBL] [Abstract][Full Text] [Related]
60. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]